(Received for publication May 1 1, 1994) The synthesis and antibacterial activities of 7/^[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-AT,AT-dimethylcarbamoyloxymethyl-3-cephem-4-carboxylic acid (El 100) and its analogs are described, as well as oral absorbability and in vivo activities of the l-(isopropoxycarbonyloxy)ethyl ester (El 101) and its analogous esters. The introduction of acyclic and cyclic lower alkyl groups at the Af-position of 3-carbamoyloxymethyl cephems influences antibacterial activities, especially against H. influenzae, and oral absorbability of their prodrug esters. The structure-activity relationships are also discussed.
Since the discovery of cefteram pivoxil1} and cefixime2), a number of orally active cephalosporins3~9) bearing an aminothiazole rnoiety at the C-7 side chain have been reported and developed, such as cefpodoxime proxetil3) (CPDX-PR) ( Fig. 1 ) and cefdinir4) (CFDN) (Fig. 2) . Compared with first generation oral cephalosporins like cephalexin and cefaclor (CCL), these newly developed compoundsshow a wider antibacterial spectrum and high stability against various /Mactamases, and consequently, have made a great contribution to the treatment of infectious diseases. Mucheffort in this field has been made to find a more well-balanced and more active compound with better oral bioavailability9).
In the course of our research program, we have found that 7-[(Z) JV,JV'-carbonyldiimidazole method1 1} (Method a) and another is the isocyanate method (Method b). Scheme 3 illustrates the general route from 7-protected 3-substituted carbamoyloxy cephems to aminothiazolyl cephem carboxylic acids and their prodrug esters. Scheme 4 describes the synthetic route for 7V-methylpiperazine cephems, because they were synthesized from 3-hydroxymethyl cephem oxide (13). Scheme 5 shows the route for anti hydroxyimino cephem (9v) . In Scheme 1 (Method a), benzhydryl 3-hydroxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylate (2a) or 7-formamido-3-hydroxymethyl cephem (2b) was synthesized by acylation at the C-7 position of 7-ACAwith (2-thienyl)acetyl chloride or formic acid-acetic anhydride, hydrolysis of acetoxy substituent at the C-3 position with bran-enzyme and esterification of the C-4 carboxylic acid with diphenyldiazomethane, following the procedure reported in a previous paper10). The hydroxymethyl group was converted with Scheme 1. (E)-hydroxyimino compound (8v) and the (Z) isomer (8u). The isolated (E)-isomer by chromatography was converted through deprotection and purification by a similar manner to that described in Scheme3 to 7-[(£)-2-(2-aminothiazol-4-yl)- 2-hydroxyiminoacetamido] -cephem (9v).
Antibacterial Activity and Oral Absorption The in vitro antibacterial activity of the new cephalosporins (9c~v) against selected Gram-positive and Gram-negative bacteria is shown in Table 1 compared with that of CCL, cefpodoxime (GPDX), and CFDN. Table 2 shows that the urinary recovery (%) after oral administration of their pivaloyloxymethyl (POM) esters (10c~10s) (20 mg/kg as the parent compound) to mice and the relative bioavailability (%) calculated according to the following equation.
Relative Bioavailability (BA%) = (Urinary recovery (%) after po dosage) (Urinary recovery (%) after iv dosage)
xlOO Most of the new tested compounds showed potent activity against Gram-positive and Gram-negative bacteria including /Mactamase producing strains except for P. aeruginosa PAO1. In general, the antibacterial activities of hydroxyimino derivatives (9c~9p) against Gram-positive bacteria especially S. aureus were higher than those of methoxy and other alkoxy derivatives (9q~9t). The hydroxyimino cephems (9c~9p) exhibited as potent against S. aureus as CFDN,and more potent than CPDX,while they showed more potent against Gram-negative bacteria than both CFDNand CPDX.
In the series of hydroxyimino derivatives, the modification with a more lipophilic substituent at the C-3 position of the nucleus resulted in slight reduction in activity but still maintenance in strong potency against most members of the Enterobacteriaceae. Like 9p, which was acylated with a basic amine such as TV-methylpiperazine, the introduction of basic amines at the C-3 position led to significant reduction in potency against both Gram-positive bacteria and Gram-negative bacteria. Therefore, the modification of the carbamoyloxy substituent seemed to be rather disappointing with respect to in vitro antibacterial activities. However, as for the activity against H. influenzae, which is a very important pathogen in respiratory tract infection, the disubstituted analogues (9i~9o) generally were more potent than monosubstituted (9d~9h) and non-substituted (9c)13) carbamoyloxymethyl cephems. Amongmethyl derivatives such as non-substituted (9c), monomethyl (9d) and dimethyl derivatives (9i), this tendency was confirmed in the activity against clinical isolates of H. influenzae^which is depicted in Fig. 4 . Therefore, dimethyl cephem (9i) was regarded as one of the most well-balanced compounds. Fluoromethoxyimino cephem (9t) showed very similar activity to methoxyimino cephem (9s), in spite of the report17) that fluoromethoxyimino derivatives are more potent than their counterparts of methoxyimino derivatives. The awft'-hydroxyimino isomer (9u) was found to be less active than 9i, which meansthat the (Z)-configuration of oxyimino substituent is very important for potent antibacterial activity.
As shown in Table 2 , the POMesters (10c~10s) showed modest and good bioavailability. Amongthe derivatives, JV,N-dimethyl (lOi, 10s) and AT-ethyl-iV-methyl cephems (lOj) showed good urinary recovery.
In general, JV,iV-disubstituted carbamoyloxy cephems esters showed better bioavailability than non-substituted (10c, lOq) and mono-substituted esters (lOd, lOr), except for pyrrolidine cephem (10m), iV-hydroxyethyl-Ar-methyl (10k) and morpholine (lOo). The reason why the latter two derivatives exhibited poor oral absorbability was considered to be due to their polar substituents. It is interesting that both iV,JV-dimethyl derivatives (lOi, 10s) of the series of the hydroxyimino cephems and the methoxyimino cephems exhibited good oral absorbability, which prompted us to conclude that N,iV-dimethylcabmoyloxymethyl group at the C-3 position worked as the key substituents for good oral absorption of cephem prodrugs. However, fluoromethoxyimnio cephem (lOt) showed less bioavailability. Therefore, it was difficult to anticipate the oral absoption of cephemprodrugs simply from their chemical structures.
Since hydroxyimino N,iV-dimethylcarbamoyloxy cephem (lOi) showed well-balanced antibacterial activity and good oral absorbability, a series of other prodrug esters were synthesized and evaluated. Table   3 shows the bioavailability of various types of prodrug esters (llb~llj). Among the series of N,JV-dimethylcarbamoyloxy cephems (lOi, lla~llj), the POMester (lOi), 2-ethylbutyryloxymethyl ester (lib), l-(isopropoxycarbonyloxy)ethyl ester (llh) and l-(cyclohexyloxycarbonyloxy)ethyl esters (Hi) exhibited good bioavailability.
On the other hand, less lipophilic esters like lla, llf, llg, llj showed poor bioavailability. These results mean that the lipophilicity of the prodrugs deeply affected their oral absorbability. Consequently, as shown in Table 3 , the modification of cephem carboxylic acid (9i) to prodrug type esters such as lib, llh, Hi resulted in about 7-fold increase in oral absorbability, while 9i showed only 6% bioavailability after oral administration. Since some iV,JV-dimethylcarbamoyloxy cephems exhibited good oral absorbability, several prodrugs (lOi and Ha, lib, llf, llh, Hi) were evaluated further for their in vivo activity. As shown in Table 3 , the POMester (lOi) and the l-(isopropoxycarbonyloxy)ethyl ester (llh) were found to be effective against S. aureus E31290 and E. coli E01 125. It is still not clear why the cyclohexyl compound (Hi) was not effective in vivo, even though Hi showed good oral absorbability. Now, we assume that this discrepancy happened due to the difference in absorption between non-infected mice and infected mice.
In summary, N,N-dimethylcarbamoyloxy cephem (9i, El 100) showed potent and well-balanced antibacterial activity and its prodrug esters exhibited good oral absorption and excellent in vivo efficacy. Considering the safety of the ester moiety, the l-(isopropoxycarbonyloxy)ethyl prodrug (llh, El 101) was chosen as a candidate for further evaluation.
Experimental *H NMRspectra were recorded on a Varian UNITY400 spectrometer. IR spectra were measured on a Hitachi 260-30 or a Nicolet 205 FT-IR spectrometer. Melting points were taken on a Yamato MP21.
Determination of Antibacterial Activities
All the in vitro antibacterial activities are given as MICin^g/ml required to prevent growth of bacterial culture. MICs were determined by the serial agar dilution method after incubation at 37°C for 18~20 hours with an inoculumn size of about 106 cells/ml.
Oral Absorption Study
Male ICR-strain mice aged 4 weeks weighing 24~30 g were used in groups of 4. The antibiotics were given to mice orally as a single dose of 20mg/kg in a suspension of 0.5% CMCand intravenously at 20mg/kg as a solution. Urine was collected over 6 hours after dosing.
To a solution of benzhydryl 7-(2-thienylacetamicio)-3-hydroxymethyl-3-cephem-4-carboxylate1 0) (la; 30 g, 0.058 mol) in tetrahydrofuran (600 ml) was added iV,iV-carbonyldiimidazole (1 1.25 g, 0.069 mol) under ice cooling, and the mixture was stirred at the same temperature for 3 hours. The mixture was diluted with ethyl acetate (1 liter) , and the organic layer was washed with water (0.4 liter). To the extract was added a solution of 50%aqueous dimethylamine (12g, 0.075 mol) under ice cooling, and the reaction mixture was stirred for 1 hour. The mixture was washed with brine, dried over anhydrous MgSO4and concentrated DEC. 1994 under reduced pressure to give a mixture of benzhydryl 7-(2-thienylacetamido)-3-iV,iV-dimethylcarbamoyloxymethyl-3 -cephem-4-carboxylate and benzhydryl 7-(2-thienylacetamido)-3 -JV,A^dimethylcarbamoyloxy-methyl-2-cephem-4-carboxylate (24 g).
To a solution of the compoundsobtained above in tetrahydrofuran (400ml) under ice cooling was added a solution of ra-chloroperoxybenzoic acid (20 g, 0.1 16mol) in tetrahydrofuran (100ml), and the mixture was stirred at the same temperature for 30 minutes. The mixture was concentrated under reduced pressure, and the residue was washed with ethyl ether. The residue was purified by silica gel column chromatography (eluent; «-hexane -ethyl acetate, 3 : 1). The fractions containing the desired compound were collected and evaporated under reduced pressure to give 7.5g of 5i (21% Benzhydryl 7-(2-Thienylacetamido)-3 -iV,iV-dimethylcarbamoyloxymethyl-3 -cephem-4-carboxylate (6i) To a solution of 5i (5 g, 8.2mmol) in N,iV-dimethylformamide (50ml) under ice cooling was added phosphorus trichloride (2.5 g, 1 8 mmol), and the mixture was stirred at the same temperature for 30 minutes. The reaction mixture was diluted with ethyl acetate (500 ml), and the organic layer was washed with water and then with brine, and dried over anhydrous MgSO4.The filtrate was concentrated under reduced pressure, and to the residue was added a solution of acetone -diisopropyl ether, and the precipitate was collected by filitration to give 3.8g of6i (79% Preparation of 6k, 60 was carried out by a method similar to that described for 6i.
Benzhydryl hydrochloride (7i)
To a solution of phosphorous pentachloride (2.8g, 13mmol) and pyridine (1.04g, 13mmol) in dichloromethane (80ml) at -10°C was added 6i (1.6 g, 2.7mmol), and the mixture was stirred at the same temperature for 1 hour. 1,3-Propanediol (1 ml) was added to the reaction mixture at -20°C. After stirring for I hour, methanol (10ml) was added to the mixture and the resulting mixture was heated to room temperature. The mixture was diluted with water (50ml), and the organic layer was washed with water and dried over anhydrous MgSO4. The extract was evaporated in vacuo, and the residue was crystallized from ethyl ether and diisopropyl ether to give l.Og of7i (74% 
acid (15; 1.9 g, 2.8 mmol) and 1 -hydroxybenztriazole (0.4 g, 2.9 mmol) in JV,AT-dimethylformamide (20 ml), AT,N' -dicyclohexylcarbodiimide (0.6g, 2.9mmol) was added and the mixture was stirred for 30minutes. To the resulting mixture were added 7i (1.3 g, 2.8mmol) and triethylamine (2.8g, 2.8mmol), and the mixture was stirred for 3hours. The mixture was diluted with ethyl acetate (300 ml). After being filtered off, the filtrate was washed with water and brine, and dried over anhydrous MgSO4. The filtrate was evaporated under reduced pressure, and the residue was chromatographed on a column of silica gel (WakoC-200, 50g). The column was eluted with «-hexane -ethyl acetate (2 : 1). The fractions containing the desired product were collected and evaporated. The residue was solidified with diisopropyl ether to give 1.4 g of 8i as an amorphous powder (45%).
Preparation of 8k, 8o was carried out by a method similar to that described for 8i. The spectral data for 8i, 8k, 8o are listed in Table 4 .
Benzhydryl 7-Formamido-3-hydroxymethyl-3-cephem-4-carboxylate (lb) 1 0) A mixture of 99% formic acid (17g, 370mmol) and acetic anhydride (7.5 g, 73.5mmol) was stirred at 40°C for 30 minutes. To the reaction mixture was added 7-amino-3-acetoxymethyl-3-cephem-4-carboxylic acid (10 g, 37 mmol) in several portions at room temperature, and the mixture was stirred for 2 hours. The mixture was concentrated under reduced pressure, and the residue was dissolved in methanol (40 ml). To the mixture was added sodium acetate (4.5g, 55mmol), and the mixture was stirred for 20minutes. TO the resulting mixture was added diisopropyl ether (160 ml), and the crystals were collected on a filter and DEC. 1994 washed with diisopropyl ether to give 1 1 g of sodium 7-formamido-3-acetoxymethyl-3-cephem-4-carboxylate (93%).
To a solution of phosphate buffer (pH 6.5, 200 ml) were added sodium 7-formamido-3-acetoxymethyl-3-cephem-4-carboxylate (5 g, 15.5 mmol) and wheat bran (32g), and the mixture was stirred for 18 hours. After being filtered off, a solution of diphenyldiazomethane (4 g, 55 mmol) in dichloromethane (8 ml) was added to the filtrate.
The pH of the mixture was adjusted to 2.8 by adding of 1 m hydrochloric acid, and the mixture was stirred for 14hours at 20°C. The organic layer was washed with water and then brine, and dried over anhydrous MgSO4. The filtrate was evaporated to dryness, and the residue was crystallized from diisopropyl ether to give 1.15g of lb (16% Benzhydryl 7-Formamido-3-(1 -piperidinyl)carbonyloxymethyl-3-cephem-4-carboxylate-1 -oxide (5n) (Method a)
To a solution of lb (4.24g, lOmmol) in tetrahydrofuran (80ml) under ice cooling was added JV,AT'-carbonyldiimidazole (1.62g, lOmmol) , and the mixture was stirred for 2hours. To the reaction mixture, piperidine (1.02g, 12mmol) was added and the mixture was stirred for 18hours at the same temperature. The mixture was evaporated in vacuo, and the residue was dissolved in ethyl acetate (200 ml). The organic layer was washed with water and then with brine, and dried over anhydrous MgSO4.The filtrate was concentrated under reduced pressure, and the residue was chromatographed on a column of silica gel (Wako C-200, 100 g). The column was eluted with «-hexane -ethyl acetate (2 : 1), and the fractions containing the desired product were collected and evaporated to give 2.3g of benzhydryl 7-formamido-3-(l-piperidinyl)carbonyloxymethyl-2-cephem-4-carboxylate as an amorphous powder (43%). MP.185~188°C
(dec), XH NMR (CDC13) To a solution of benzhydryl 7-formamido-3-( l -piperidinyl)carbonyloxymethyl-2-cephem-4-carboxylate (3.4g, 6.3 mmol) in ethyl acetate (20ml) was added m-chloroperoxybenzoic acid (1.53 g, 8.9mmol ) under ice cooling, and the mixture was stirred at the sametemperature for 35 minutes. The reaction mixture was evaporated under reduced pressure, and the residue was chromatographed on a column of silica gel (Wako C-200, 100 g). The column was eluted with dichloromethane -ethyl acetate (4 : 1). The fractions containing the desired product were collected and evaporated. The residue was crystallized from diisopropyl ether to give 1.53g of5n (44% Benzhydryl 7-Formamido-3-( 1 -piperidinyl)carbonyloxymethyl-3-cephem-4-carboxylate (6n)
To a solution of 5n (2.07g, 3.9mmol) in Ar,AT-dimethylformamide (25ml) at -20°C was added phosphorous trichloride (l ml, 1 1 mmol), and the reaction mixture was stirred at the same temperature for 35 minutes. The mixture was diluted with ethyl acetate (300ml), and organic layer was washed with water and then brine, and dried over anhydrous MgSO4.The filtrate was evaporated under reduced pressure, and the residue was purified by chromatography on a silica gel 50g; eluent; 3: 1) . The fractions containing the desired compound were collected and evaporated. The residue was crystallized from diisopropyl ether to give 1.87 g of 6n as crystals (93% Preparation of 6g, 6h, 6j, 61, 6m was carried out by a method similar to that described for 6n.
To a solution of6n (1.87 g, 35 mmol) in tetrahydrofuran (10ml) and methanol (10ml) was added 12m hydrochloric acid (3ml, 36mmol), and the mixture was stirred at room temperature for 2hours. After VOL.47 NO. 12 THE JOURNAL OF ANTIBIOTICS 1519 evaporation, the mixture was added to a solution of ethyl acetate and water. Theorganic layer waswashed with water and then brine, and dried over anhydrous MgSO4.After being distilled off, the crude product of 7-amino cephem (7n) was obtained.
To a solution of 15 (2.35g, 3.5mmol ) and 1-hydroxybenztriazole (0.56g, 4.1mmol ) in N,JV-dimethylformamide (18 ml) was added JV,JV'-dicyclohexylcarbodiimide (0.79 g, 3.8 mmol), and the mixture was stirred for 1 hour. To the resulting mixture was added 7n (1.3 g, 2. 8mmol), and the mixture was stirred for 3 hours. The mixture was diluted with ethyl acetate (300ml) and after the precipitate was filtered off, the filtrate was washed with water and then brine, and dried over anhydrous MgSO4.The filtrate was evaporated under reduced pressure, and the residue waschromatographedon a columnof silica gel (Wako C-200, 50g) . The column was eluted with «-hexane-ethyl acetate (2 : 1). The fractions containing the desired product were collected and evaporated. The residue was solidified from diisopropyl ether to give 1.4g of8n as an amorphous powder (34%).
Preparation of 8d~8h, 8j, 81, 8m was carried out by a method similar to that described for 8n. The spectral data for 8d~8h, 8j, 81~8n are listed in Table 4 .
Benzhydryl 7-Formamido-3-ALmethylcarbamoyloxymethyl-3-cephem-4-carboxylate-1 -oxide (5d) (Method b) To a solution of lb (10 g, 24mmol) in tetrahydrofuran (70 ml) were added methylisocyanate (13.9 ml, 240 mmol) and triethylamine (0.33ml, 0.24mmol), and the mixture was stirred at 50°C for 8hours in a sealed bottle. The mixture was diluted with ethyl acetate (500 ml), and the organic layer was washed with water and then brine, and dried over anhydrous MgSO4. The filtrate was evaporated and purified by column chromatography of silica gel (Wako C-200 200 g; eluent; dichloromethane-ethyl acetate, 2 : 1) and the fractions containing the desired product were collected and evaporated to give 9.34 g of benzhydryl 7-formamido-3-7V-methylcarbamoyloxymethyl-2-cephem-4-carboxylate (38%). *H NMR(CDC13) 6 2.55 To a solution of the z!2-cephem obtained above (9.3 g, 19.3 mmol) in a solution ofethyl acetate (100 ml) and tetrahydrofuran (50 ml) under ice cooling was added ra-chloroperoxybenzoic acid (4.76 g, 19 mmol), and the mixutre was stirred for 30 minutes. To the mixutre was added ethyl ether (400 ml), and the precipitate was collected to give 5.9g of 5d (62% Preparation of 6e-6f was carried out by a method similiar to that described for 6d.
To a solution ofanisole (2 ml) and trifluoroacetic acid (3 ml) under ice-cooling was added the compound 8i (1.4 g, 1.3 mmol) , and the mixture was stirred at room temperature for 1 hour. The solvent was evaporated in vacuo and the residue was triturated with diisopropyl ether (100 ml). The precipitate was collected by filtration and was added to a solution of 90% formic acid (10 ml). After being stirred at room temperature for 3 hours, the mixture was concentrated, and the residue was triturated with diisopropyl ether. The crystals were collected by filtration and mixed with sodium acetate (262 mg, 3.2 mmol) in methanol (10 ml). The mixture was evaporated to dryness, and the residue was triturated with 2-propanol. The precipitate was collected by filtration to give a crude product of 9i. The solid was chromatographed on a column of C18 Silica Gel (YMCA-343, eluent; 5% methanol). The fractions containing the desired compound were DEC. 1994 concentrated under reduced pressure, and the residue was freeze-dried to give 240 mg of 9i (39%).
Preparation of 9d~9p was carried out by a method similar to that described for 9i. The spectral data of various derivatives 9d~9p are listed in Table 5 .
Preparation of 8s, 8r, 8t, was carried out by a method similar to that described for 8i, using 16, 1713) instead of 15.
The spectral data for various derivatives 8r~8t are listed in Table 4 .
To a solution of anisole (10 ml) and trifluoroacetic acid (20 ml) under ice-cooling was added 8s (1.46 g, 1.6mmol), and the mixture was stirred at roomtemperature for 2hours. The solvent was evaporated in vacuo, and the residue was triturated with diisopropylether (100 ml). The precipitate collected by filtration was mixed with sodium acetate (600mg, 7.3 mmol) in methanol (15ml). The mixture was evaporated to dryness, and the residue was solidified from 2-propanol. The precipitate was collected by filtration to give a crude product of 9s. The solid was purified by chromatography on a column of C18 Silica Gel (YMC A-343, eluent; 5%methanol). The fractions containing the desired compound were concentrated under reduced pressure and the residue was freeze-dried to give 71 mg of 9s (8.5%).
Preparation of 9r, 9t was carried out by a method similar to that described for 9s. The spectral data for derivatives 9r-9t are listed in Table 5 .
To a solution of 9i (80mg, 0.16mmol) in iV,JV-dimethylformamide (2ml) was added iodomethyl pivalate (37 mg, 0.16 mmol) dropwise under ice cooling. The mixture was stirred at the same temperature for 30 minutes and diluted with ethyl acetate. The reaction mixture was washed with water and then brine, and dried over anhydrous MgSO4. The filtrate was concentrated in vacuo, and the residue was triturated with diisopropyl ether (50ml) to yield 21 mg of lOi as an amorphous powder (23%).
Preparation of 10c~10t, lla-llj was carried out by a method similar to that described for lOi. The spectral data of various derivatives 10c-lOt, lla-llj are listed in Table 6 and Table 7 .
Benzhydryl 7-Formamido-3-(4-methyl-1 -piperazinyl)carbonyloxymethyl-3-cephem-4-carboxylate-1 -oxide (5p) To a solution of benzhydryl 7-formamido-3-hydroxymethyl-3-cephem-4-carboxylatel -oxide (13; 22 g, 0.05mol) in tetrahydrofuran (200ml) under ice cooling was added JV,iV-carbonyldiimidazole (8.8 g, 0.055mol), and the reaction mixture was strirred at the same temperature for 1 hour. To the reaction mixture were added N-methylpiperazine (10.25 g, 0. 125 mol) and water (10 ml), and the mixture was stirred for 3 hours. The mixture was diluted with ethyl acetate (500 ml). The mixture was washed with water and then brine, dried over MgSO4and concentrated under reduced pressure to give the crude desired product. The residue was purified by silica gel column chromatography (eluent; dichloromethane -methanol, 80 : 20) to afford 2.3g of5p (8% Benzhydryl 7-[(Z)-2-(2-Tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido] -3-(4-methyl-l -piperazinyl)carbonyloxymethyl-3-cephem-4-carboxylate-1 -oxide hydrochloride (8p) To a solution of 5p (10.6g, 18.7mol) in tetrahydrofuran (100ml) and methanol (50ml) was added 1 m hydrochloric acid (10ml), and the mixture was stirred at room temperature for 6 hours. After being evaporated, ethyl ether (300 ml) was added to the residue and the resulting precipitate was collected by filtration to give 10.3 g of 7-amino cephem (7p) (90%). To a solution of 7p (9.25 g, 15.2mol) in iV,JV-dimethylformamide (18ml) and triethylamine (2. DEC. 1994 16.9mol), 15 (10.2g, 15.2mol) were added JV,iV-dicyclohexylcarbidiimide (3.13g, 15.2mol ) and 1-hydroxybenztriazole (2.05 g, 15.2mol), and the mixture was stirred at room temperature for 2hours. The precipitate was removed by filtration and the filtrate was diluted with «-hexane (700ml). The oily product was collected by decantation and the residue was purified by silica gel column chromatography (eluent; dichloromethane-methanol, 98 :2) to give 3.1 g of 8p (17% 7-[(Z)-2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido] -3-(4-methyll -piperazinyl)carbonyloxymethyl-3-cephem-4-carboxylic acid ditrifluoroacetate (9p) To a solution of8p (4.0 g, 3.4 mmol) in dichloromethane (24 ml) under ice cooling was added phosphorus trichloride (2.3g, 16.8mmol) , and the mixture was stirred at the same temperature for 1 hour. To the reaction mixture was added «-hexane (500 ml), and the precipitate was collected by filtration. The residue was added to a solution of anisole (25 ml) and trifluoroacetic acid (33 ml), and the mixture was stirred for 1 hour and diluted with diisopropyl ether (200 ml). The precipitate was collected through filtration and was added to a solution of 90%formic acid (25 ml). After being stirred for 2hours, the reaction mixture was diluted with a solution of ethyl acetate (100ml) and diisopropyl ether (100ml), and the precipitate was filtered off to give crude 9p, which was chromatographed on a column of C18 Silica Gel (YMCA-343; eluent; 1 -10% methanol -0. 1 %trifluoroacetic acid). The fractions containing the desired compound were concentrated under reduced pressure, and the residue was freeze-dried to provide 200 mgof 9p (8%).
The spectral data of 9p are listed in Table 5 .
Benzhydryl 7-[(£)-2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido] -3-Ar,Ar-dimethylcarbamoyl oxyymethyl-3 -cephem-4-carboxylate (8v) To a solution of8u (6.05 g, 6.9 mmol) in acetonitrile (70 ml) was added 12m hydrochloric acid (1.97 ml), and the mixture was stirred for 20 hours at room temperature and adjusted to pH 6 with sodium bicarbonate solution. To the mixture were added ethyl acetate (250ml) and water (200ml), and the organic layer was separated. The organic layer was evaporated to dryness and the residue was chromatographedon a column of silica gel eluent; 4: 1) . The fractions containing the desired product were collected and evaporated to give 1.03 g of8v (17%). XH NMR(CDC13) S 2.84 (3H, s), 2.89
